Quantum Biopharma (NASDAQ:QNTM) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Quantum Biopharma (NASDAQ:QNTM) from a sell rating to a hold rating in a research report report published on Saturday morning.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Quantum Biopharma in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Quantum Biopharma Stock Down 10.3%

Shares of QNTM stock opened at $4.28 on Friday. Quantum Biopharma has a 12 month low of $2.07 and a 12 month high of $38.25. The business’s 50 day moving average is $3.91 and its two-hundred day moving average is $8.69. The company has a market cap of $16.35 million, a PE ratio of -0.49 and a beta of 0.33.

Quantum Biopharma (NASDAQ:QNTM) last issued its quarterly earnings data on Thursday, March 26th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.49). As a group, equities analysts expect that Quantum Biopharma will post -3.27 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Jane Street Group LLC bought a new stake in shares of Quantum Biopharma in the fourth quarter valued at approximately $80,000. Virtu Financial LLC bought a new position in Quantum Biopharma during the fourth quarter worth $76,000. Finally, Steward Partners Investment Advisory LLC bought a new position in Quantum Biopharma during the second quarter worth $63,000. 1.24% of the stock is currently owned by institutional investors and hedge funds.

About Quantum Biopharma

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.